Blocking inflammasome activity by a caspase-1 inhibitor (VX765) prevented the proliferation of immune cells within CCA plaques after stroke and attenuated the invasion of pro-inflammatory circulating monocytes (Fig. 2c,d). Here, CASP1 is linked to stroke disorder.